APO Research
Talk to an analyst

APO RESEARCH · REPORT

Dry Eye Syndrome Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Dry Eye Syndrome Drugs Market Analysis and Forecast 2026-2032

23 December 2025200 pages

Choose your research edition.

Industry ResearchDry Eye Syndrome Drugs Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Dry Eye Syndrome Drugs Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Dry Eye Syndrome Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dry Eye Syndrome Drugs Market Outlook and Growth Opportunities 2026209 pages · $4,250 USDMarket Analysis & ForecastGlobal Dry Eye Syndrome Drugs Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Dry Eye Syndrome Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Dry Eye Syndrome Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Dry Eye Syndrome Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Dry Eye Syndrome Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Dry Eye Syndrome Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Dry Eye Syndrome Drugs include Johnson & Johnson, Novartis, United Laboratories, Jianfeng Group, AbbVie, URSAPHARM, Thea pharmaceuticals, Sun Pharmaceutical and SIMILASAN, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Dry Eye Syndrome Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Dry Eye Syndrome Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Dry Eye Syndrome Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Dry Eye Syndrome Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Dry Eye Syndrome Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Dry Eye Syndrome Drugs revenue, projected growth trends, production technology, application and end-user industry.

Dry Eye Syndrome Drugs Segment by Company

Johnson & Johnson

Novartis

United Laboratories

Jianfeng Group

AbbVie

URSAPHARM

Thea pharmaceuticals

Sun Pharmaceutical

SIMILASAN

Santen Pharma

Rohto

Prestige Consumer Healthcare

OmniVision Pharma

LION

Kenvue (VISINE)

Bausch & Lomb

Alcon

Akorn

Dry Eye Syndrome Drugs Segment by Type

Artificial Tears

Anti-inflammatory Drugs

Other

Dry Eye Syndrome Drugs Segment by Application

Homecare

Hospitals

Clinics

Others

Dry Eye Syndrome Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dry Eye Syndrome Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dry Eye Syndrome Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dry Eye Syndrome Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Dry Eye Syndrome Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Dry Eye Syndrome Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Dry Eye Syndrome Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Dry Eye Syndrome Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Artificial Tears Major Player Table 3. Anti-inflammatory Drugs Major Player Table 4. Other Major Player Table 5. Global Dry Eye Syndrome Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Homecare Major Player Table 7. Hospitals Major Player Table 8. Clinics Major Player Table 9. Others Major Player Table 10. Dry Eye Syndrome Drugs Industry Trends Table 11. Dry Eye Syndrome Drugs Industry Drivers Table 12. Dry Eye Syndrome Drugs Industry Opportunities and Challenges Table 13. Dry Eye Syndrome Drugs Industry Restraints Table 14. Global Dry Eye Syndrome Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Dry Eye Syndrome Drugs Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Dry Eye Syndrome Drugs Market Share by Region (2021-2026) Table 17. Global Dry Eye Syndrome Drugs Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Dry Eye Syndrome Drugs Market Share by Region (2027-2032) Table 19. Global Dry Eye Syndrome Drugs Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Dry Eye Syndrome Drugs Revenue Market Share by Players (2021-2026) Table 21. Global Dry Eye Syndrome Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Dry Eye Syndrome Drugs Key Players Headquarters & Area Served Table 23. Global Dry Eye Syndrome Drugs Players, Product Type & Application Table 24. Global Dry Eye Syndrome Drugs Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Dry Eye Syndrome Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Dry Eye Syndrome Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Dry Eye Syndrome Drugs Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Dry Eye Syndrome Drugs Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Dry Eye Syndrome Drugs Revenue Market Share by Type (2021-2026) Table 31. Global Dry Eye Syndrome Drugs Revenue Market Share by Type (2027-2032) Table 32. Global Dry Eye Syndrome Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Dry Eye Syndrome Drugs Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Dry Eye Syndrome Drugs Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Dry Eye Syndrome Drugs Revenue Market Share by Application (2021-2026) Table 36. Global Dry Eye Syndrome Drugs Revenue Market Share by Application (2027-2032) Table 37. Johnson & Johnson Company Information Table 38. Johnson & Johnson Business Overview Table 39. Johnson & Johnson Dry Eye Syndrome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Johnson & Johnson Dry Eye Syndrome Drugs Product Portfolio Table 41. Johnson & Johnson Recent Development Table 42. Novartis Company Information Table 43. Novartis Business Overview Table 44. Novartis Dry Eye Syndrome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Novartis Dry Eye Syndrome Drugs Product Portfolio Table 46. Novartis Recent Development Table 47. United Laboratories Company Information Table 48. United Laboratories Business Overview Table 49. United Laboratories Dry Eye Syndrome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. United Laboratories Dry Eye Syndrome Drugs Product Portfolio Table 51. United Laboratories Recent Development Table 52. Jianfeng Group Company Information Table 53. Jianfeng Group Business Overview Table 54. Jianfeng Group Dry Eye Syndrome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Jianfeng Group Dry Eye Syndrome Drugs Product Portfolio Table 56. Jianfeng Group Recent Development Table 57. AbbVie Company Information Table 58. AbbVie Business Overview Table 59. AbbVie Dry Eye Syndrome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. AbbVie Dry Eye Syndrome Drugs Product Portfolio Table 61. AbbVie Recent Development Table 62. URSAPHARM Company Information Table 63. URSAPHARM Business Overview Table 64. URSAPHARM Dry Eye Syndrome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. URSAPHARM Dry Eye Syndrome Drugs Product Portfolio Table 66. URSAPHARM Recent Development Table 67. Thea pharmaceuticals Company Information Table 68. Thea pharmaceuticals Business Overview Table 69. Thea pharmaceuticals Dry Eye Syndrome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Thea pharmaceuticals Dry Eye Syndrome Drugs Product Portfolio Table 71. Thea pharmaceuticals Recent Development Table 72. Sun Pharmaceutical Company Information Table 73. Sun Pharmaceutical Business Overview Table 74. Sun Pharmaceutical Dry Eye Syndrome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Sun Pharmaceutical Dry Eye Syndrome Drugs Product Portfolio Table 76. Sun Pharmaceutical Recent Development Table 77. SIMILASAN Company Information Table 78. SIMILASAN Business Overview Table 79. SIMILASAN Dry Eye Syndrome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. SIMILASAN Dry Eye Syndrome Drugs Product Portfolio Table 81. SIMILASAN Recent Development Table 82. Santen Pharma Company Information Table 83. Santen Pharma Business Overview Table 84. Santen Pharma Dry Eye Syndrome Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Santen Pharma Dry Eye Syndrome Drugs Product Portfolio Table 86. Santen Pharma Recent Development Table 87. Rohto Company Information Table 88. Rohto Business Overview Table 89. Rohto Dry Eye Syndrome Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. Rohto Dry Eye Syndrome Drugs Product Portfolio Table 91. Rohto Recent Development Table 92. Prestige Consumer Healthcare Company Information Table 93. Prestige Consumer Healthcare Business Overview Table 94. Prestige Consumer Healthcare Dry Eye Syndrome Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. Prestige Consumer Healthcare Dry Eye Syndrome Drugs Product Portfolio Table 96. Prestige Consumer Healthcare Recent Development Table 97. OmniVision Pharma Company Information Table 98. OmniVision Pharma Business Overview Table 99. OmniVision Pharma Dry Eye Syndrome Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. OmniVision Pharma Dry Eye Syndrome Drugs Product Portfolio Table 101. OmniVision Pharma Recent Development Table 102. LION Company Information Table 103. LION Business Overview Table 104. LION Dry Eye Syndrome Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. LION Dry Eye Syndrome Drugs Product Portfolio Table 106. LION Recent Development Table 107. Kenvue (VISINE) Company Information Table 108. Kenvue (VISINE) Business Overview Table 109. Kenvue (VISINE) Dry Eye Syndrome Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. Kenvue (VISINE) Dry Eye Syndrome Drugs Product Portfolio Table 111. Kenvue (VISINE) Recent Development Table 112. Bausch & Lomb Company Information Table 113. Bausch & Lomb Business Overview Table 114. Bausch & Lomb Dry Eye Syndrome Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 115. Bausch & Lomb Dry Eye Syndrome Drugs Product Portfolio Table 116. Bausch & Lomb Recent Development Table 117. Alcon Company Information Table 118. Alcon Business Overview Table 119. Alcon Dry Eye Syndrome Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 120. Alcon Dry Eye Syndrome Drugs Product Portfolio Table 121. Alcon Recent Development Table 122. Akorn Company Information Table 123. Akorn Business Overview Table 124. Akorn Dry Eye Syndrome Drugs Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 125. Akorn Dry Eye Syndrome Drugs Product Portfolio Table 126. Akorn Recent Development Table 127. North America Dry Eye Syndrome Drugs Revenue by Type (2021-2026) & (US$ Million) Table 128. North America Dry Eye Syndrome Drugs Revenue by Type (2027-2032) & (US$ Million) Table 129. North America Dry Eye Syndrome Drugs Revenue by Application (2021-2026) & (US$ Million) Table 130. North America Dry Eye Syndrome Drugs Revenue by Application (2027-2032) & (US$ Million) Table 131. North America Dry Eye Syndrome Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. North America Dry Eye Syndrome Drugs Revenue by Country (2021-2026) & (US$ Million) Table 133. North America Dry Eye Syndrome Drugs Revenue by Country (US$ Million) & (2027-2032) Table 134. Europe Dry Eye Syndrome Drugs Revenue by Type (2021-2026) & (US$ Million) Table 135. Europe Dry Eye Syndrome Drugs Revenue by Type (2027-2032) & (US$ Million) Table 136. Europe Dry Eye Syndrome Drugs Revenue by Application (2021-2026) & (US$ Million) Table 137. Europe Dry Eye Syndrome Drugs Revenue by Application (2027-2032) & (US$ Million) Table 138. Europe Dry Eye Syndrome Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 139. Europe Dry Eye Syndrome Drugs Revenue by Country (2021-2026) & (US$ Million) Table 140. Europe Dry Eye Syndrome Drugs Revenue by Country (US$ Million) & (2027-2032) Table 141. China Dry Eye Syndrome Drugs Revenue by Type (2021-2026) & (US$ Million) Table 142. China Dry Eye Syndrome Drugs Revenue by Type (2027-2032) & (US$ Million) Table 143. China Dry Eye Syndrome Drugs Revenue by Application (2021-2026) & (US$ Million) Table 144. China Dry Eye Syndrome Drugs Revenue by Application (2027-2032) & (US$ Million) Table 145. Asia Dry Eye Syndrome Drugs Revenue by Type (2021-2026) & (US$ Million) Table 146. Asia Dry Eye Syndrome Drugs Revenue by Type (2027-2032) & (US$ Million) Table 147. Asia Dry Eye Syndrome Drugs Revenue by Application (2021-2026) & (US$ Million) Table 148. Asia Dry Eye Syndrome Drugs Revenue by Application (2027-2032) & (US$ Million) Table 149. Asia Dry Eye Syndrome Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 150. Asia Dry Eye Syndrome Drugs Revenue by Region (US$ Million) & (2021-2026) Table 151. Asia Dry Eye Syndrome Drugs Revenue by Region (US$ Million) & (2027-2032) Table 152. SAMEA Dry Eye Syndrome Drugs Revenue by Type (2021-2026) & (US$ Million) Table 153. SAMEA Dry Eye Syndrome Drugs Revenue by Type (2027-2032) & (US$ Million) Table 154. SAMEA Dry Eye Syndrome Drugs Revenue by Application (2021-2026) & (US$ Million) Table 155. SAMEA Dry Eye Syndrome Drugs Revenue by Application (2027-2032) & (US$ Million) Table 156. SAMEA Dry Eye Syndrome Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 157. SAMEA Dry Eye Syndrome Drugs Revenue by Country (2021-2026) & (US$ Million) Table 158. SAMEA Dry Eye Syndrome Drugs Revenue by Country (US$ Million) & (2027-2032) Table 159. Research Programs/Design for This Report Table 160. Authors List of This Report Table 161. Secondary Sources Table 162. Primary Sources List of Figures Figure 1. Dry Eye Syndrome Drugs Image Figure 2. Global Dry Eye Syndrome Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dry Eye Syndrome Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Artificial Tears Image Figure 5. Anti-inflammatory Drugs Image Figure 6. Other Image Figure 7. Global Dry Eye Syndrome Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Dry Eye Syndrome Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 9. Homecare Image Figure 10. Hospitals Image Figure 11. Clinics Image Figure 12. Others Image Figure 13. Global Dry Eye Syndrome Drugs Market Size (US$ Million) & (2021-2032) Figure 14. Global Dry Eye Syndrome Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Dry Eye Syndrome Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Dry Eye Syndrome Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Dry Eye Syndrome Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Dry Eye Syndrome Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Dry Eye Syndrome Drugs Revenue Market Share by Type (2021-2032) Figure 21. Global Dry Eye Syndrome Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Dry Eye Syndrome Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Dry Eye Syndrome Drugs Revenue Market Share by Application (2021-2032) Figure 24. North America Dry Eye Syndrome Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Dry Eye Syndrome Drugs Revenue Share by Type (2021-2032) Figure 26. North America Dry Eye Syndrome Drugs Revenue Share by Application (2021-2032) Figure 27. North America Dry Eye Syndrome Drugs Revenue Share by Country (2021-2032) Figure 28. United States Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Dry Eye Syndrome Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Dry Eye Syndrome Drugs Revenue Share by Type (2021-2032) Figure 33. Europe Dry Eye Syndrome Drugs Revenue Share by Application (2021-2032) Figure 34. Europe Dry Eye Syndrome Drugs Revenue Share by Country (2021-2032) Figure 35. Germany Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Dry Eye Syndrome Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Dry Eye Syndrome Drugs Revenue Share by Type (2021-2032) Figure 45. China Dry Eye Syndrome Drugs Revenue Share by Application (2021-2032) Figure 46. Asia Dry Eye Syndrome Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Dry Eye Syndrome Drugs Revenue Share by Type (2021-2032) Figure 48. Asia Dry Eye Syndrome Drugs Revenue Share by Application (2021-2032) Figure 49. Asia Dry Eye Syndrome Drugs Revenue Share by Region (2021-2032) Figure 50. Japan Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Dry Eye Syndrome Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Dry Eye Syndrome Drugs Revenue Share by Type (2021-2032) Figure 58. SAMEA Dry Eye Syndrome Drugs Revenue Share by Application (2021-2032) Figure 59. SAMEA Dry Eye Syndrome Drugs Revenue Share by Country (2021-2032) Figure 60. Brazil Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Dry Eye Syndrome Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Artificial Tears
  • Anti-inflammatory Drugs
  • Other
Applications
  • Homecare
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Johnson & Johnson
  • Novartis
  • United Laboratories
  • Jianfeng Group
  • AbbVie
  • URSAPHARM
  • Thea pharmaceuticals
  • Sun Pharmaceutical
  • SIMILASAN
  • Santen Pharma
  • Rohto
  • Prestige Consumer Healthcare
  • OmniVision Pharma
  • LION
  • Kenvue (VISINE)
  • Bausch & Lomb
  • Alcon
  • Akorn

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Dry Eye Syndrome Drugs Market by Type
  3. 1.2.1 Global Dry Eye Syndrome Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Artificial Tears
  5. 1.2.3 Anti-inflammatory Drugs
  6. 1.2.4 Other
  7. 1.3 Dry Eye Syndrome Drugs Market by Application
  8. 1.3.1 Global Dry Eye Syndrome Drugs Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Homecare
  10. 1.3.3 Hospitals
  11. 1.3.4 Clinics
  12. 1.3.5 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Dry Eye Syndrome Drugs Market Dynamics
  1. 2.1 Dry Eye Syndrome Drugs Industry Trends
  2. 2.2 Dry Eye Syndrome Drugs Industry Drivers
  3. 2.3 Dry Eye Syndrome Drugs Industry Opportunities and Challenges
  4. 2.4 Dry Eye Syndrome Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Dry Eye Syndrome Drugs Market Perspective (2021-2032)
  2. 3.2 Global Dry Eye Syndrome Drugs Growth Trends by Region
  3. 3.2.1 Global Dry Eye Syndrome Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Dry Eye Syndrome Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Dry Eye Syndrome Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Dry Eye Syndrome Drugs Revenue by Players
  2. 4.1.1 Global Dry Eye Syndrome Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Dry Eye Syndrome Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Dry Eye Syndrome Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Dry Eye Syndrome Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Dry Eye Syndrome Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Dry Eye Syndrome Drugs Players, Product Type & Application
  8. 4.5 Global Dry Eye Syndrome Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Dry Eye Syndrome Drugs Market CR5 and HHI
  11. 4.6.3 2025 Dry Eye Syndrome Drugs Tier 1, Tier 2, and Tier 3
5 Dry Eye Syndrome Drugs Market Size by Type
  1. 5.1 Global Dry Eye Syndrome Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Dry Eye Syndrome Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Dry Eye Syndrome Drugs Revenue Market Share by Type (2021-2032)
6 Dry Eye Syndrome Drugs Market Size by Application
  1. 6.1 Global Dry Eye Syndrome Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Dry Eye Syndrome Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Dry Eye Syndrome Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Johnson & Johnson
  2. 7.1.1 Johnson & Johnson Company Information
  3. 7.1.2 Johnson & Johnson Business Overview
  4. 7.1.3 Johnson & Johnson Dry Eye Syndrome Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Johnson & Johnson Dry Eye Syndrome Drugs Product Portfolio
  6. 7.1.5 Johnson & Johnson Recent Developments
  7. 7.2 Novartis
  8. 7.2.1 Novartis Company Information
  9. 7.2.2 Novartis Business Overview
  10. 7.2.3 Novartis Dry Eye Syndrome Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis Dry Eye Syndrome Drugs Product Portfolio
  12. 7.2.5 Novartis Recent Developments
  13. 7.3 United Laboratories
  14. 7.3.1 United Laboratories Company Information
  15. 7.3.2 United Laboratories Business Overview
  16. 7.3.3 United Laboratories Dry Eye Syndrome Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 United Laboratories Dry Eye Syndrome Drugs Product Portfolio
  18. 7.3.5 United Laboratories Recent Developments
  19. 7.4 Jianfeng Group
  20. 7.4.1 Jianfeng Group Company Information
  21. 7.4.2 Jianfeng Group Business Overview
  22. 7.4.3 Jianfeng Group Dry Eye Syndrome Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Jianfeng Group Dry Eye Syndrome Drugs Product Portfolio
  24. 7.4.5 Jianfeng Group Recent Developments
  25. 7.5 AbbVie
  26. 7.5.1 AbbVie Company Information
  27. 7.5.2 AbbVie Business Overview
  28. 7.5.3 AbbVie Dry Eye Syndrome Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 AbbVie Dry Eye Syndrome Drugs Product Portfolio
  30. 7.5.5 AbbVie Recent Developments
  31. 7.6 URSAPHARM
  32. 7.6.1 URSAPHARM Company Information
  33. 7.6.2 URSAPHARM Business Overview
  34. 7.6.3 URSAPHARM Dry Eye Syndrome Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 URSAPHARM Dry Eye Syndrome Drugs Product Portfolio
  36. 7.6.5 URSAPHARM Recent Developments
  37. 7.7 Thea pharmaceuticals
  38. 7.7.1 Thea pharmaceuticals Company Information
  39. 7.7.2 Thea pharmaceuticals Business Overview
  40. 7.7.3 Thea pharmaceuticals Dry Eye Syndrome Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Thea pharmaceuticals Dry Eye Syndrome Drugs Product Portfolio
  42. 7.7.5 Thea pharmaceuticals Recent Developments
  43. 7.8 Sun Pharmaceutical
  44. 7.8.1 Sun Pharmaceutical Company Information
  45. 7.8.2 Sun Pharmaceutical Business Overview
  46. 7.8.3 Sun Pharmaceutical Dry Eye Syndrome Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Sun Pharmaceutical Dry Eye Syndrome Drugs Product Portfolio
  48. 7.8.5 Sun Pharmaceutical Recent Developments
  49. 7.9 SIMILASAN
  50. 7.9.1 SIMILASAN Company Information
  51. 7.9.2 SIMILASAN Business Overview
  52. 7.9.3 SIMILASAN Dry Eye Syndrome Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 SIMILASAN Dry Eye Syndrome Drugs Product Portfolio
  54. 7.9.5 SIMILASAN Recent Developments
  55. 7.10 Santen Pharma
  56. 7.10.1 Santen Pharma Company Information
  57. 7.10.2 Santen Pharma Business Overview
  58. 7.10.3 Santen Pharma Dry Eye Syndrome Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Santen Pharma Dry Eye Syndrome Drugs Product Portfolio
  60. 7.10.5 Santen Pharma Recent Developments
  61. 7.11 Rohto
  62. 7.11.1 Rohto Company Information
  63. 7.11.2 Rohto Business Overview
  64. 7.11.3 Rohto Dry Eye Syndrome Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Rohto Dry Eye Syndrome Drugs Product Portfolio
  66. 7.11.5 Rohto Recent Developments
  67. 7.12 Prestige Consumer Healthcare
  68. 7.12.1 Prestige Consumer Healthcare Company Information
  69. 7.12.2 Prestige Consumer Healthcare Business Overview
  70. 7.12.3 Prestige Consumer Healthcare Dry Eye Syndrome Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Prestige Consumer Healthcare Dry Eye Syndrome Drugs Product Portfolio
  72. 7.12.5 Prestige Consumer Healthcare Recent Developments
  73. 7.13 OmniVision Pharma
  74. 7.13.1 OmniVision Pharma Company Information
  75. 7.13.2 OmniVision Pharma Business Overview
  76. 7.13.3 OmniVision Pharma Dry Eye Syndrome Drugs Revenue and Gross Margin (2021-2026)
  77. 7.13.4 OmniVision Pharma Dry Eye Syndrome Drugs Product Portfolio
  78. 7.13.5 OmniVision Pharma Recent Developments
  79. 7.14 LION
  80. 7.14.1 LION Company Information
  81. 7.14.2 LION Business Overview
  82. 7.14.3 LION Dry Eye Syndrome Drugs Revenue and Gross Margin (2021-2026)
  83. 7.14.4 LION Dry Eye Syndrome Drugs Product Portfolio
  84. 7.14.5 LION Recent Developments
  85. 7.15 Kenvue (VISINE)
  86. 7.15.1 Kenvue (VISINE) Company Information
  87. 7.15.2 Kenvue (VISINE) Business Overview
  88. 7.15.3 Kenvue (VISINE) Dry Eye Syndrome Drugs Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Kenvue (VISINE) Dry Eye Syndrome Drugs Product Portfolio
  90. 7.15.5 Kenvue (VISINE) Recent Developments
  91. 7.16 Bausch & Lomb
  92. 7.16.1 Bausch & Lomb Company Information
  93. 7.16.2 Bausch & Lomb Business Overview
  94. 7.16.3 Bausch & Lomb Dry Eye Syndrome Drugs Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Bausch & Lomb Dry Eye Syndrome Drugs Product Portfolio
  96. 7.16.5 Bausch & Lomb Recent Developments
  97. 7.17 Alcon
  98. 7.17.1 Alcon Company Information
  99. 7.17.2 Alcon Business Overview
  100. 7.17.3 Alcon Dry Eye Syndrome Drugs Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Alcon Dry Eye Syndrome Drugs Product Portfolio
  102. 7.17.5 Alcon Recent Developments
  103. 7.18 Akorn
  104. 7.18.1 Akorn Company Information
  105. 7.18.2 Akorn Business Overview
  106. 7.18.3 Akorn Dry Eye Syndrome Drugs Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Akorn Dry Eye Syndrome Drugs Product Portfolio
  108. 7.18.5 Akorn Recent Developments
8 North America
  1. 8.1 North America Dry Eye Syndrome Drugs Revenue (2021-2032)
  2. 8.2 North America Dry Eye Syndrome Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Dry Eye Syndrome Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Dry Eye Syndrome Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Dry Eye Syndrome Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Dry Eye Syndrome Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Dry Eye Syndrome Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Dry Eye Syndrome Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Dry Eye Syndrome Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Dry Eye Syndrome Drugs Revenue by Country
  11. 8.6.1 North America Dry Eye Syndrome Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Dry Eye Syndrome Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Dry Eye Syndrome Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Dry Eye Syndrome Drugs Revenue (2021-2032)
  2. 9.2 Europe Dry Eye Syndrome Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Dry Eye Syndrome Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Dry Eye Syndrome Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Dry Eye Syndrome Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Dry Eye Syndrome Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Dry Eye Syndrome Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Dry Eye Syndrome Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Dry Eye Syndrome Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Dry Eye Syndrome Drugs Revenue by Country
  11. 9.6.1 Europe Dry Eye Syndrome Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Dry Eye Syndrome Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Dry Eye Syndrome Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Dry Eye Syndrome Drugs Revenue (2021-2032)
  2. 10.2 China Dry Eye Syndrome Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Dry Eye Syndrome Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Dry Eye Syndrome Drugs Revenue by Type (2027-2032)
  5. 10.3 China Dry Eye Syndrome Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Dry Eye Syndrome Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Dry Eye Syndrome Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Dry Eye Syndrome Drugs Revenue by Application (2027-2032)
  9. 10.5 China Dry Eye Syndrome Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Dry Eye Syndrome Drugs Revenue (2021-2032)
  2. 11.2 Asia Dry Eye Syndrome Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Dry Eye Syndrome Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Dry Eye Syndrome Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Dry Eye Syndrome Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Dry Eye Syndrome Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Dry Eye Syndrome Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Dry Eye Syndrome Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Dry Eye Syndrome Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Dry Eye Syndrome Drugs Revenue by Country
  11. 11.6.1 Asia Dry Eye Syndrome Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Dry Eye Syndrome Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Dry Eye Syndrome Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Dry Eye Syndrome Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Dry Eye Syndrome Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Dry Eye Syndrome Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Dry Eye Syndrome Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Dry Eye Syndrome Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Dry Eye Syndrome Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Dry Eye Syndrome Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Dry Eye Syndrome Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Dry Eye Syndrome Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Dry Eye Syndrome Drugs Revenue by Country
  11. 12.6.1 SAMEA Dry Eye Syndrome Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Dry Eye Syndrome Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Dry Eye Syndrome Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst